David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$397M |
| 2 |
YHOO
Yahoo Inc
YHOO
|
+$342M |
| 3 |
Bank of America
BAC
|
+$322M |
| 4 |
Citigroup
C
|
+$260M |
| 5 |
Booking.com
BKNG
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$637M |
| 2 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$397M |
| 3 |
Gilead Sciences
GILD
|
+$358M |
| 4 |
Phillips 66
PSX
|
+$330M |
| 5 |
Apple
AAPL
|
+$320M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.78% |
| 2 | Technology | 11.11% |
| 3 | Financials | 10% |
| 4 | Consumer Discretionary | 8.83% |
| 5 | Communication Services | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALEX
1801
DELISTED
Alexander & Baldwin
ALEX
| $2.16M | ﹤0.01% |
+58,938
| New | +$1.94M |
|
|
ASNA
1802
PUT
DELISTED
Ascena Retail Group, Inc.
ASNA
| $2.16M | ﹤0.01% |
9,770
| – | – |
|
1803
Cytokinetics
CYTK
$11.1B
| $2.16M | ﹤0.01% |
306,426
-78,114
| -20% | -$571K |
|
|
WCC
1804
PUT
WESCO International
WCC
$16.9B
| $2.16M | ﹤0.01% |
39,500
-25,300
| -39% | -$1.12M |
|
1805
SouthState Bank Corp
SSB
$10.3B
| $2.16M | ﹤0.01% |
33,562
+9,051
| +37% | +$583K |
|
|
EBIX
1806
CALL
DELISTED
Ebix Inc
EBIX
| $2.15M | ﹤0.01% |
+52,800
| New | +$1.84M |
|
|
GCP
1807
DELISTED
GCP Applied Technologies Inc.
GCP
| $2.15M | ﹤0.01% |
+107,945
| New | +$1.96M |
|
1808
CALL
Zions Bancorporation
ZION
$9.99B
| $2.15M | ﹤0.01% |
88,800
+37,900
| +74% | +$872K |
|
|
BCOV
1809
DELISTED
Brightcove, Inc.
BCOV
| $2.15M | ﹤0.01% |
344,309
+24,625
| +8% | +$143K |
|
|
SREV
1810
DELISTED
ServiceSource International, Inc.
SREV
| $2.15M | ﹤0.01% |
503,638
-28,107
| -5% | -$114K |
|
|
SQI
1811
DELISTED
SCIQUEST, INC. COMMON STOCK
SQI
| $2.15M | ﹤0.01% |
154,503
+13,257
| +9% | +$167K |
|
|
CAI
1812
DELISTED
CAI International, Inc.
CAI
| $2.14M | ﹤0.01% |
221,610
+9,583
| +5% | +$72.1K |
|
1813
CALL
Factset
FDS
$10.5B
| $2.14M | ﹤0.01% |
14,100
-10,900
| -44% | -$1.63M |
|
1814
CALL
Vertex Pharmaceuticals
VRTX
$139B
| $2.13M | ﹤0.01% |
26,800
| – | – |
|
|
ZNGA
1815
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $2.13M | ﹤0.01% |
933,947
+26,334
| +3% | +$58.9K |
|
|
BLUE
1816
CALL
DELISTED
bluebird bio
BLUE
| $2.13M | ﹤0.01% |
3,860
| – | – |
|
|
MNK
1817
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $2.13M | ﹤0.01% |
34,682
-283,691
| -89% | -$18.1M |
|
|
ICPT
1818
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.12M | ﹤0.01% |
+16,493
| New | +$1.95M |
|
1819
CALL
Applied Materials
AMAT
$379B
| $2.12M | ﹤0.01% |
100,000
-748,900
| -88% | -$13.7M |
|
1820
Texas Capital Bancshares
TCBI
$4.28B
| $2.12M | ﹤0.01% |
+55,149
| New | +$2.04M |
|
|
AMRN
1821
Amarin Corp
AMRN
$304M
| $2.12M | ﹤0.01% |
69,138
-6,531
| -9% | -$194K |
|
|
HSII
1822
DELISTED
Heidrick & Struggles
HSII
| $2.11M | ﹤0.01% |
89,025
+21,626
| +32% | +$524K |
|
1823
PUT
Herc Holdings
HRI
$5.19B
| $2.11M | ﹤0.01% |
+66,667
| New | +$1.96M |
|
1824
PUT
L3Harris
LHX
$48.9B
| $2.1M | ﹤0.01% |
+27,000
| New | +$2.16M |
|
1825
CALL
VeriSign
VRSN
$26.6B
| $2.09M | ﹤0.01% |
23,600
-23,900
| -50% | -$1.95M |
|
Similar funds
David Shaw's Q1 2016 Portfolio in Review
As of Q1 2016, David Shaw held 4,137 positions worth $55.7B, down 17% from $67.2B the previous quarter. Its ten largest holdings account for 9.5% of the portfolio.
David Shaw withdrew a net $9.72B in Q1 2016, closing 773 positions and reducing 1,495 holdings. Its most notable exit was PRECISION CASTPARTS CORP, an estimated $637M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
Against the trend, David Shaw opened a new position in EQT Corp worth $47.6M.
- David Shaw's largest Q1 2016 buy was EQT Corp: 1,300,361 shares worth $47.6M.
- David Shaw added most to Allergan plc in Q1 2016, an estimated $397M increase.
- David Shaw's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $358M.
- David Shaw fully exited PRECISION CASTPARTS CORP in Q1 2016, selling an estimated $637M.
- David Shaw's ten largest holdings make up 9.5% of its $55.7B portfolio in Q1 2016.
- David Shaw opened 382 new positions and closed 773 in Q1 2016.
- David Shaw's portfolio value fell 17% quarter-over-quarter to $55.7B.
Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.